Candel Therapeutics, Inc. (CADL)

Candel Therapeutics, Inc.'s stock price has been impacted by several events in the past six months. The company reported a significant miss in its Fourth Quarter 2025 earnings per share (EPS). Candel Therapeutics experienced a substantially wider net loss in Q4 2025. A public offering in February 2026 led to share dilution. The company has announced positive clinical trial data and presented new data. As of April 12, 2026, analysts have given Candel Therapeutics a consensus "Hold" rating.

Candel Therapeutics, Inc. does not produce or sell commercial products subject to traditional demand seasonality. The demand for Candel Therapeutics is primarily from investors and collaborators interested in funding its research and development efforts. Therefore, there is no discernible seasonality in the demand for its products or services.

Candel Therapeutics, Inc. (CADL) is a clinical-stage biopharmaceutical company focused on developing multimodal biological and viral immunotherapies for cancer. The company's approach involves genetically modified adenovirus and herpes simplex virus (HSV) gene constructs to induce an anti-tumor immune response in solid tumors. Its lead product candidate CAN-2409 is in Phase 3 for localized prostate cancer, Phase 2a for non-small cell lung cancer (NSCLC), and Phase 2 for borderline resectable pancreatic cancer. CAN-3110 is in Phase 1b clinical trials for recurrent high-grade glioma. The enLIGHTEN™ Discovery Platform is an HSV-based platform for creating new viral immunotherapies.

Candel Therapeutics, Inc. is headquartered in Needham, Massachusetts, United States. Its operations focus on research, development, and clinical trials, conducted in collaboration with clinical sites and research organizations.

Candel Therapeutics' brand reputation is shaped by its scientific advancements and financial performance. Positive clinical trial data and regulatory designations contribute positively to its reputation. Financial events, such as the earnings miss and public offering, could negatively impact its reputation among investors. Continued progress in its clinical pipeline and institutional investor backing suggest belief in its long-term potential.

Candel Therapeutics, Inc. has a diverse ownership structure. Approximately 32.27% of the stock is held by institutional shareholders. Company insiders own about 24.06% of the stock. Retail investors hold approximately 43.67% of the company's stock. Estuardo Aguilarcordova is the largest individual shareholder, owning 7.16 million shares.